OTCMKTS:PBSV Pharma-Bio Serv (PBSV) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free PBSV Stock Alerts $0.65 -0.05 (-7.14%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$0.65▼$0.6550-Day Range$0.65▼$0.8952-Week Range$0.57▼$1.10Volume890 shsAverage Volume2,956 shsMarket Capitalization$14.92 millionP/E Ratio21.67Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Pharma-Bio Serv alerts: Email Address Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Pharma-Bio Serv Stock (OTCMKTS:PBSV)Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.Read More PBSV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBSV Stock News HeadlinesMay 23, 2024 | americanbankingnews.comPharma-Bio Serv (OTCMKTS:PBSV) Stock Passes Below 200 Day Moving Average of $0.89May 18, 2024 | wsj.comPharma-Bio Serv Inc.May 14, 2024 | msn.comKörber Pharma and Siemens Take the Lead in ABI Research's MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive RankingMay 2, 2024 | markets.businessinsider.comBBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024April 25, 2024 | markets.businessinsider.comDeep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)April 25, 2024 | markets.businessinsider.comEQS-News: Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché LaboratóriosApril 23, 2024 | markets.businessinsider.comBiomarin Pharmaceutical earnings preview: what Wall Street is expectingApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market ExpectationsApril 9, 2024 | tmcnet.comSanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com's Supplier Pre-assessment ProgramApril 3, 2024 | benzinga.comLooking Into Biomarin Pharmaceutical's Recent Short InterestMarch 19, 2024 | finance.yahoo.comPBSV Releases Quarterly ResultsMarch 19, 2024 | seekingalpha.comPharma-Bio Serv reports Q1 resultsMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial OutlookMarch 4, 2024 | markets.businessinsider.comMaintaining Hold on BridgeBio Pharma Amidst Bayer Partnership and Market UncertaintiesFebruary 26, 2024 | marketwatch.comBioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- UpdateFebruary 23, 2024 | markets.businessinsider.comStrong Voxzogo Performance Underpins Buy Rating for BioMarin PharmaceuticalJanuary 30, 2024 | finance.yahoo.comPBSV Expands Margins and MarketsJanuary 28, 2024 | msn.comJubilant Pharma Plans Stake Sale in Sofie Biosciences Amid Merger DealJanuary 9, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Rating for BridgeBio Pharma with Promising Treatment Launches and Strategic Growth DriversJanuary 8, 2024 | seekingalpha.comBridgeBio Pharma's Robust Pipeline Could Benefit From A PartnerJanuary 3, 2024 | finance.yahoo.comPBSV Reward Shareholders with High YieldDecember 21, 2023 | finanznachrichten.dePharma-Bio Serv Inc.: Pharma-Bio Serv Announces Special DividendDecember 8, 2023 | msn.comAbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?November 28, 2023 | markets.businessinsider.comBioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In GermanyNovember 7, 2023 | markets.businessinsider.comPromising Future for BridgeBio Pharma: Lebovitz’s Buy Rating Backed by Potential Blockbusters and Pipeline AssetsSee More Headlines Receive PBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/30/2024Next Earnings (Estimated)6/12/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Management consulting services Sub-IndustryN/A Current SymbolOTCMKTS:PBSV CUSIPN/A CIK1304161 Webwww.pharmabioserv.com Phone(787) 278-2709Fax787-796-5168Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio21.67 Forward P/E Ratio8.13 P/E GrowthN/ANet Income$1.31 million Net Margins4.05% Pretax Margin5.65% Return on Equity3.95% Return on Assets3.10% Debt Debt-to-Equity RatioN/A Current Ratio5.10 Quick Ratio5.10 Sales & Book Value Annual Sales$16.98 million Price / Sales0.88 Cash Flow$0.06 per share Price / Cash Flow10.69 Book Value$0.70 per share Price / Book0.93Miscellaneous Outstanding Shares22,960,000Free Float20,162,000Market Cap$14.92 million OptionableNot Optionable Beta0.55 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Victor Sanchez (Age 53)CEO, President & President of European Operations Comp: $323.67kMr. Pedro J. Lasanta (Age 64)CFO, VP of Finance & Administration and Secretary Comp: $225.6kMs. Elizabeth Plaza (Age 60)Founder & Senior Strategic Consultant Comp: $69.92kMs. Miriam Marrero M.B.A.Human Resources ManagerKey CompetitorsLightbridgeNASDAQ:LTBRLichen ChinaNASDAQ:LICNIssuer DirectNYSE:ISDRTSSOTCMKTS:TSSIWilhelmina InternationalNASDAQ:WHLMView All Competitors PBSV Stock Analysis - Frequently Asked Questions How have PBSV shares performed in 2024? Pharma-Bio Serv's stock was trading at $1.05 at the beginning of 2024. Since then, PBSV stock has decreased by 38.1% and is now trading at $0.65. View the best growth stocks for 2024 here. Are investors shorting Pharma-Bio Serv? Pharma-Bio Serv saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,000 shares, an increase of 4,900.0% from the April 30th total of 100 shares. Based on an average daily trading volume, of 5,400 shares, the short-interest ratio is presently 0.9 days. View Pharma-Bio Serv's Short Interest. When is Pharma-Bio Serv's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our PBSV earnings forecast. How were Pharma-Bio Serv's earnings last quarter? Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) announced its quarterly earnings data on Monday, March, 18th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.03. The business earned $2.38 million during the quarter, compared to the consensus estimate of $5 million. Pharma-Bio Serv had a trailing twelve-month return on equity of 3.95% and a net margin of 4.05%. How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv? Pharma-Bio Serv announced a dividend on Thursday, December 21st. Shareholders of record on Tuesday, January 30th will be paid a dividend of $0.075 per share on Thursday, February 15th. The ex-dividend date of this dividend is Monday, January 29th. Read our dividend analysis for PBSV. What other stocks do shareholders of Pharma-Bio Serv own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE). How do I buy shares of Pharma-Bio Serv? Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PBSV) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma-Bio Serv, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.